TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00338845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share Safer Sex program
Description: The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard didactic safer-sex counseling program
Description: The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
Study: NCT04316845

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine PET/CT
Description: Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
Study: NCT03218046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Eye Movement Desensitisation and Reprocessing
Study: NCT00561925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine IR
Description: 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nevirapine XR
Description: 400 mg QD
Study: NCT02664935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: FGFR Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: MTORC1/2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: ALK/MET/ROS1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: MEK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane, anti-mitotic cytotoxic chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AKT Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFRm+ T790M+ Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PDL1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PDL1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: VEGFR Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: ATR inhibitor
Study: NCT00852449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrictive and liberal fluid therapy
Description: In both group, when hypovolemia is suspected (peak aortic velocity variation \> 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrictive and liberal fluid therapy
Description: In both group, when hypovolemia is suspected (peak aortic velocity variation \> 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV
Study: NCT05173558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted motionless standing
Description: Participants remained 20 minutes of uninterrupted motionless standing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted motionless sitting
Description: Participants remained 20 minutes of uninterrupted motionless sitting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-to-stand transitions
Description: 20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
Study: NCT00684021

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult stem cells
Description: One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult stem cells
Description: One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time infusion of 30 ml of HSA (5%)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time infusion of 30 ml of HSA (5%)
Study: NCT00891904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergoing Radiotherapy
Study: NCT04123392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT03965611

Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.

Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.

Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.

Intervention type: PROCEDURE
Intervention: Rectal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.

Intervention type: PROCEDURE
Intervention: Rectal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.

Intervention type: PROCEDURE
Intervention: Rectal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.

Intervention type: PROCEDURE
Intervention: Disability rating scale (DRS-F)
Description: Will be assessed at day 90 +/- 7 days.

Intervention type: PROCEDURE
Intervention: Disability rating scale (DRS-F)
Description: Will be assessed at day 90 +/- 7 days.
Study: NCT04292678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention matched control
Description: Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
Study: NCT03141008

Intervention type: OTHER
Intervention: Fibroscan changes with different diets
Description: Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens

Intervention type: OTHER
Intervention: Fibroscan changes with different diets
Description: Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
Study: NCT00718354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Once daily dose of 1mg/Kg of body weight for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Investigator's discretion
Study: NCT03339128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT02795429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
Study: NCT03167931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI + transcranial Magnetic Stimulation
Description: Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI + transcranial Magnetic Stimulation
Description: Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial electric stimulation + electroencephalogram
Description: Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial electric stimulation + electroencephalogram
Description: Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
Study: NCT00793000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 75 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 75 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 150 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 150 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 300 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 300 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 750 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 750 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1000 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1000 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1250 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1250 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1500 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1500 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 300 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 300 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 750 mg oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 750 mg oral dose (prepared solution), given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1000 mg oral dose (prepared solution), given once
Study: NCT03200600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study: NCT00988520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Intubation dose of 0.6 mg/kg injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Intubation dose of 0.6 mg/kg injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Intubation dose of 0.9 mg/kg injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Intubation dose of 0.9 mg/kg injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 0.5-2.0% intravenous maintenance anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 0.5-2.0% intravenous maintenance anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4010 mg/kg/hr intravenous maintenance anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4010 mg/kg/hr intravenous maintenance anesthesia
Study: NCT02234245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine System
Description: Telemedicine System is used in remote monitoring group
Study: NCT01435382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose A - single-dose intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose B - single-dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose C - single-dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose D - single-dose subcutaneous injection
Study: NCT00780312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: 50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
Study: NCT00416910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT02976038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: 40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
Study: NCT03632889

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GoToSleep Program
Description: For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
Study: NCT03473054

Intervention type: OTHER
Intervention: Web-based Mindfulness Course
Description: The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources.